Trial Profile
A phase I, dose-escalation, open-label, multicenter study of iodine-131, anti-B1 antibody [iodine-131 tositumomab] for intermediate- and high-risk B-cell chronic lymphocytic leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Iodine-131 tositumomab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 25 Sep 2005 New trial record.